中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 5
May  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(5): 888-899

Association of serum exosomal miR-122-5p with the prognosis of hepatic confluent necrosis and fibrosis in patients with chronic hepatitis B

DOI: 10.12449/JCH250514
  • 1.

    Department of Hepatology，The Fifth Medical Center of Chinese PLA General Hospital，Beijing 100039，China

  • 2.

    Medical School of Chinese PLA，Beijing 100853，China

  • 3.

    Department of Gastroenterology，Hainan Hospital of Chinese PLA General Hospital，Sanya，Hainan 572013，China

Research funding:

National Science and Technology Major Project during the 13th Five-Year Plan Period (2018ZX10725-506);

Research and Translational Application of Clinical Characteristic Diagnosis and Treatment Technology in the Capital (Z221100007422002)

More Information
  • Corresponding author: YANG Yongping， yongpingyang@hotmail.com （ORCID： 0000-0002-8307-1095）
  • Received Date: 2024-10-17
  • Accepted Date: 2024-12-16
  • Published Date: 2025-05-25
    Abstract
  •   Objective  To investigate the association of serum exosomal microRNAs （miRNAs） with hepatic inflammatory injury and histological outcomes in patients with chronic hepatitis B （CHB）.  Methods  Peripheral serum samples were collected from six healthy adults and six patients with CHB， and size exclusion chromatography was used to extract exosomes. Small RNA sequencing and transcriptomic analysis were used to identify the serum exosomal miRNAs associated with liver inflammatory injury and fibrosis， and quantitative real-time PCR was used for validation in a mouse model of acute liver injury induced by lipopolysaccharide/D-galactosamine， a rat model of liver fibrosis induced by carbon tetrachloride， and 84 CHB patients undergoing liver biopsy twice before and after treatment. The independent-samples t test was used for comparison of normally distributed continuous data between two groups； an analysis of variance was used for comparison between multiple groups， and the Tukey test was used for further comparison between two groups. The Mann-Whitney U test was used for comparison of non-normally distributed continuous data between two groups； the Kruskal-Wallis H test was used for comparison between multiple groups， and the Dunn test was used for further comparison between two groups. The chi-square test or the Fisher’s exact test was used for comparison of categorical data between groups. The univariate and multivariate Logistic regression analyses were used to investigate influencing factors.  Results  Abnormal expression of serum exosomal miR-122-5p was observed in patients with CHB， and it was downregulated in patients with confluent necrosis and advanced fibrosis. In the mouse model of acute liver injury and the rat model of liver fibrosis， compared with the control group， the model group had a significant reduction in the expression level of miR-122-5p in the liver （P=0.048 and 0.014）， and compared with the patients with mild liver injury， the patients with severe confluent necrosis and advanced fibrosis showed a significant reduction in the expression level of miR-122-5p in liver tissue （P<0.05）. Among the 84 CHB patients， the patients with severe hepatic confluent necrosis or advanced liver fibrosis had a significantly lower expression level of serum exosomal miR-122-5p than those with mild liver injury （P<0.001 and P=0.003）. The multivariate Logistic regression analysis showed that the expression level of miR-122-5p was an independent influencing factor for confluent necrosis （odds ratio ［OR］=0.001， 95% confidence interval ［CI］： 0.000‍ ‍—‍ ‍0.037， P=0.005） and liver fibrosis degree （OR=0.568， 95%CI： 0.331‍ ‍—‍ ‍0.856， P=0.019）. In addition， compared with the patients with low expression of miR-122-5p， the patients with high expression of miR-122-5p before treatment had a significantly higher reversal rate of liver fibrosis after 72 weeks of antiviral therapy （64.3% vs 38.1%， P=0.029）.  Conclusion  Serum exosomal miR-122-5p in CHB patients is closely associated with the progression of hepatic confluent necrosis and fibrosis， and the reduction in the expression level of miR-122-5p may aggravate hepatic confluent necrosis， promote the progression of fibrosis， and affect the histological outcome of CHB patients after antiviral therapy.

     

    • FullText(HTML)
  • loading
    • References(41)
  • [1]
    RONG GH, CHEN YP, YU ZJ, et al. Synergistic effect of Biejia-Ruangan on fibrosis regression in patients with chronic hepatitis B treated with entecavir: A multicenter, randomized, double-blind, placebo-controlled trial[J]. J Infect Dis, 2022, 225( 6): 1091- 1099. DOI: 10.1093/infdis/jiaa266.
    [2]
    MARCELLIN P, GANE E, BUTI M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study[J]. Lancet, 2013, 381( 9865): 468- 475. DOI: 10.1016/S0140-6736(12)61425-1.
    [3]
    ROCKEY DC, CALDWELL SH, GOODMAN ZD, et al. Liver biopsy[J]. Hepatology, 2009, 49( 3): 1017- 1044. DOI: 10.1002/hep.22742.
    [4]
    ISHAK K, BAPTISTA A, BIANCHI L, et al. Histological grading and staging of chronic hepatitis[J]. J Hepatol, 1995, 22( 6): 696- 699. DOI: 10.1016/0168-8278(95)80226-6.
    [5]
    JAY HL. Scheuer’s liver biopsy interpretation[M]. 9th ed. Singapore: Elsevier, 2016.
    [6]
    CHEN TJ, LIAW YF. The prognostic significance of bridging hepatic necrosis in chronic type B hepatitis: A histopathologic study[J]. Liver, 1988, 8( 1): 10- 16. DOI: 10.1111/j.1600-0676.1988.tb00960.x.
    [7]
    CHANG XJ, WANG J, CHEN Y, et al. A novel nomogram to predict evident histological liver injury in patients with HBeAg-positive chronic hepatitis B virus infection[J]. EBioMedicine, 2021, 67: 103389. DOI: 10.1016/j.ebiom.2021.103389.
    [8]
    ZHU L, YANG JR, YANG LL, et al. Advances on the application of transient elastography in the diagnosis of liver fibrosis[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 3): 16- 22. DOI: 10.3969/j.issn.1674-7380.2023.03.003.

    朱璐, 杨君茹, 何玲玲, 等. 瞬时弹性成像在肝纤维化诊断中的应用研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 3): 16- 22. DOI: 10.3969/j.issn.1674-7380.2023.03.003.
    [9]
    IMBERT-BISMUT F, RATZIU V, PIERONI L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study[J]. Lancet, 2001, 357( 9262): 1069- 1075. DOI: 10.1016/S0140-6736(00)04258-6.
    [10]
    WILLIAMS AL, HOOFNAGLE JH. Ratio of serum aspartate to alanine aminotransferase in chronic hepatitis. Relationship to cirrhosis[J]. Gastroenterology, 1988, 95( 3): 734- 739. DOI: 10.1016/s0016-5085(88)80022-2.
    [11]
    WAI CT, GREENSON JK, FONTANA RJ, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C[J]. Hepatology, 2003, 38( 2): 518- 526. DOI: 10.1053/jhep.2003.50346.
    [12]
    ADAMS LA, BULSARA M, ROSSI E, et al. Hepascore: An accurate validated predictor of liver fibrosis in chronic hepatitis C infection[J]. Clin Chem, 2005, 51( 10): 1867- 1873. DOI: 10.1373/clinchem.2005.048389.
    [13]
    STERLING RK, LISSEN E, CLUMECK N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection[J]. Hepatology, 2006, 43( 6): 1317- 1325. DOI: 10.1002/hep.21178.
    [14]
    CHEN Y, WANG YJ, CHEN YP, et al. A novel noninvasive program for staging liver fibrosis in untreated patients with chronic hepatitis B[J]. Clin Transl Gastroenterol, 2019, 10( 5): 1- 12. DOI: 10.14309/ctg.0000000000000033.
    [15]
    SHEN MY, SHEN Y, FAN XL, et al. Roles of macrophages and exosomes in liver diseases[J]. Front Med(Lausanne), 2020, 7: 583691. DOI: 10.3389/fmed.2020.583691.
    [16]
    PAN Y, TAN WF, YANG MQ, et al. The therapeutic potential of exosomes derived from different cell sources in liver diseases[J]. Am J Physiol Gastrointest Liver Physiol, 2022, 322( 4): G397- G404. DOI: 10.1152/ajpgi.00054.2021.
    [17]
    JIAO Y, LU W, XU P, et al. Hepatocyte-derived exosome may be as a biomarker of liver regeneration and prognostic valuation in patients with acute-on-chronic liver failure[J]. Hepatol Int, 2021, 15( 4): 957- 969. DOI: 10.1007/s12072-021-10217-3.
    [18]
    ZHAO TT, LI JF, ZHANG LT. Progress in the potential therapeutic mechanism of mesenchymal stem cell-derived exosomes for liver fibrosis[J]. Chin J Clin Pharmacol Ther, 2024, 29( 4): 475- 480. DOI: 10.12092/j.issn.1009-2501.2024.04.017.

    赵婷婷, 李俊峰, 张立婷. 间充质干细胞源性外泌体对肝纤维化潜在治疗机制的研究进展[J]. 中国临床药理学与治疗学, 2024, 29( 4): 475- 480. DOI: 10.12092/j.issn.1009-2501.2024.04.017.
    [19]
    NIU LJ, ZHANG YM, HUANG T, et al. Exosomal microRNA-155 as a biomarker for hepatic fibrosis diagnosis and progression[J]. Ann Transl Med, 2021, 9( 2): 137. DOI: 10.21037/atm-20-7787.
    [20]
    JI D, CHEN Y, BI JF, et al. Entecavir plus Biejia-Ruangan compound reduces the risk of hepatocellular carcinoma in Chinese patients with chronic hepatitis B[J]. J Hepatol, 2022, 77( 6): 1515- 1524. DOI: 10.1016/j.jhep.2022.07.018.
    [21]
    CHANG XJ, LV CH, WANG BQ, et al. The utility of P-I-R classification in predicting the on-treatment histological and clinical outcomes of patients with hepatitis B and advanced liver fibrosis[J]. Hepatology, 2024, 79( 2): 425- 437. DOI: 10.1097/HEP.0000000000000563.
    [22]
    BÖING AN, van der POL E, GROOTEMAAT AE, et al. Single-step isolation of extracellular vesicles by size-exclusion chromatography[J]. J Extracell Vesicles, 2014, 3: 23430. DOI: 10.3402/jev.v3.23430.
    [23]
    MATEESCU B, KOWAL EJ, van BALKOM BW, et al. Obstacles and opportunities in the functional analysis of extracellular vesicle RNA- an ISEV position paper[J]. J Extracell Vesicles, 2017, 6( 1): 1286095. DOI: 10.1080/20013078.2017.1286095.
    [24]
    LOVE MI, HUBER W, ANDERS S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2[J]. Genome Biol, 2014, 15( 12): 550. DOI: 10.1186/s13059-014-0550-8.
    [25]
    YANG WC, TAO KX, ZHANG P, et al. Maresin 1 protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting macrophage pyroptosis and inflammatory response[J]. Biochem Pharmacol, 2022, 195: 114863. DOI: 10.1016/j.bcp.2021.114863.
    [26]
    YANG Y, NEMOTO EM, HARVEY SK, et al. Increased hepatic platelet activating factor(PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis[J]. Gut, 2004, 53( 6): 877- 883. DOI: 10.1136/gut.2003.024893.
    [27]
    CHEN W, SUN YM, CHEN SY, et al. Matrisome gene-based subclassification of patients with liver fibrosis identifies clinical and molecular heterogeneities[J]. Hepatology, 2023, 78( 4): 1118- 1132. DOI: 10.1097/HEP.0000000000000423.
    [28]
    Chinese Society of Hepatology, Chinese Medical Association; Chinese Society of Gastroenterology, Chinese Medical Association; Chinese Society of Infectious Diseases, Chinese Medical Association. Consensus on the diagnosis and therapy of hepatic fibrosis(2019)[J]. J Clin Hepatol, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.

    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 肝纤维化诊断及治疗共识(2019年)[J]. 临床肝胆病杂志, 2019, 35( 10): 2163- 2172. DOI: 10.3969/j.issn.1001-5256.2019.10.007.
    [29]
    SEKI E, SCHWABE RF. Hepatic inflammation and fibrosis: Functional links and key pathways[J]. Hepatology, 2015, 61( 3): 1066- 1079. DOI: 10.1002/hep.27332.
    [30]
    SUN XY, SU Y, WEE A, et al. Autoimmune hepatitis with confluent necrosis indicates severe liver injury but responds well to standard immunosuppressive therapy[J]. Histol Histopathol, 2024, 39( 7): 935- 945. DOI: 10.14670/HH-18-690.
    [31]
    PETRENKIENE V, GUDINAVICIENE I, JONAITIS L, et al. Improvement of liver histopathology in patients with hepatitis C after interferon and ribavirin combination therapy[J]. Medicina(Kaunas), 2004, 40( 10): 962- 968.
    [32]
    CHANG JH, NICOLAS E, MARKS D, et al. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1[J]. RNA Biol, 2004, 1( 2): 106- 113. DOI: 10.4161/rna.1.2.1066.
    [33]
    HSU SH, WANG B, KOTA J, et al. Essential metabolic, anti-inflammatory, and anti-tumorigenic functions of miR-122 in liver[J]. J Clin Invest, 2012, 122( 8): 2871- 2883. DOI: 10.1172/JCI63539.
    [34]
    LIU YN, CHEN WY, CHEN J, et al. miR-122-5p regulates hepatocytes damage caused by BaP and DBP co-exposure through SOCS1/STAT3 signaling in vitro[J]. Ecotoxicol Environ Saf, 2021, 223: 112570. DOI: 10.1016/j.ecoenv.2021.112570.
    [35]
    JIN Y, WONG YS, GOH BKP, et al. Circulating microRNAs as potential diagnostic and prognostic biomarkers in hepatocellular carcinoma[J]. Sci Rep, 2019, 9( 1): 10464. DOI: 10.1038/s41598-019-46872-8.
    [36]
    ZHANG YQ, ZHANG XZ, CHEN RF, et al. HSCs-derived exosomes regulate the levels of inflammatory cytokines in HIBECs through miR-122-5p mediated p38 MAPK signaling pathway[J]. Genomics, 2024, 116( 2): 110795. DOI: 10.1016/j.ygeno.2024.110795.
    [37]
    LI J, GHAZWANI M, ZHANG YF, et al. miR-122 regulates collagen production via targeting hepatic stellate cells and suppressing P4HA1 expression[J]. J Hepatol, 2013, 58( 3): 522- 528. DOI: 10.1016/j.jhep.2012.11.011.
    [38]
    TENG KY, BARAJAS JM, HU P, et al. Role of B cell lymphoma 2 in the regulation of liver fibrosis in miR-122 knockout mice[J]. Biology(Basel), 2020, 9( 7): 157. DOI: 10.3390/biology9070157.
    [39]
    WU ZY, WANG JB, FENG JY, et al. microRNA-122-5p prevents proliferation and promotes apoptosis of hepatic stellate cells by suppressing the cellular-Abelsongene/histone deacetylases 2 pathway[J]. Hum Exp Toxicol, 2022, 41: 9603271221084672. DOI: 10.1177/09603271221084672.
    [40]
    MIRZAEI HR, SAHEBKAR A, MOHAMMADI M, et al. Circulating microRNAs in hepatocellular carcinoma: Potential diagnostic and prognostic biomarkers[J]. Curr Pharm Des, 2016, 22( 34): 5257- 5269. DOI: 10.2174/1381612822666160303110838.
    [41]
    NAKAMURA M, KANDA T, JIANG X, et al. Serum microRNA-122 and Wisteria floribunda agglutinin-positive Mac-2 binding protein are useful tools for liquid biopsy of the patients with hepatitis B virus and advanced liver fibrosis[J]. PLoS One, 2017, 12( 5): e0177302. DOI: 10.1371/journal.pone.0177302.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(7)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (444) PDF downloads(39) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return